BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gonçalves A, Bertrand J, Ke R, Comets E, de Lamballerie X, Malvy D, Pizzorno A, Terrier O, Rosa Calatrava M, Mentré F, Smith P, Perelson AS, Guedj J. Timing of Antiviral Treatment Initiation is Critical to Reduce SARS-CoV-2 Viral Load. CPT Pharmacometrics Syst Pharmacol 2020;9:509-14. [PMID: 32558354 DOI: 10.1002/psp4.12543] [Cited by in Crossref: 87] [Cited by in F6Publishing: 107] [Article Influence: 43.5] [Reference Citation Analysis]
Number Citing Articles
1 Smith T, Hoyo-vadillo C, Adom AA, Favari-perozzi L, Gastine S, Dehbi H, Villegas-lara B, Mateos E, González YSP, Navarro-gualito MD, Cruz-carbajal AS, Cortes-vazquez MA, Bekker-méndez C, Aguirre-alvarado C, Aguirre-gil G, Delgado-pastelin L, Owen A, Lowe D, Standing J, Escobedo J. Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE). Trials 2022;23. [DOI: 10.1186/s13063-022-06533-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Saleh MA, Hirasawa M, Sun M, Gülave B, Elassaiss-schaap J, de Lange EC. The PBPK LeiCNS-PK3.0 framework predicts Nirmatrelvir (but not Remdesivir or Molnupiravir) to achieve effective concentrations against SARS-CoV-2 in human brain cells. European Journal of Pharmaceutical Sciences 2022. [DOI: 10.1016/j.ejps.2022.106345] [Reference Citation Analysis]
3 Elaiw AM, Alsulami RS, Hobiny AD. Modeling and Stability Analysis of Within-Host IAV/SARS-CoV-2 Coinfection with Antibody Immunity. Mathematics 2022;10:4382. [DOI: 10.3390/math10224382] [Reference Citation Analysis]
4 Akinosoglou K, Schinas G, Gogos C. Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir. Viruses 2022;14:2540. [DOI: 10.3390/v14112540] [Reference Citation Analysis]
5 Lowe DM, Brown LK, Chowdhury K, Davey S, Yee P, Ikeji F, Ndoutoumou A, Shah D, Lennon A, Rai A, Agyeman AA, Checkley A, Longley N, Dehbi HM, Freemantle N, Breuer J, Standing JF; FLARE Investigators. Favipiravir, lopinavir-ritonavir, or combination therapy (FLARE): A randomised, double-blind, 2 × 2 factorial placebo-controlled trial of early antiviral therapy in COVID-19. PLoS Med 2022;19:e1004120. [PMID: 36260627 DOI: 10.1371/journal.pmed.1004120] [Reference Citation Analysis]
6 Alamil M, Thébaud G, Berthier K, Soubeyrand S. Characterizing viral within-host diversity in fast and non-equilibrium demo-genetic dynamics. Front Microbiol 2022;13:983938. [DOI: 10.3389/fmicb.2022.983938] [Reference Citation Analysis]
7 Sanche S, Cassidy T, Chu P, Perelson AS, Ribeiro RM, Ke R. A simple model of COVID-19 explains disease severity and the effect of treatments. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-18244-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jeong YD, Ejima K, Kim KS, Joohyeon W, Iwanami S, Fujita Y, Jung IH, Aihara K, Shibuya K, Iwami S, Bento AI, Ajelli M. Designing isolation guidelines for COVID-19 patients with rapid antigen tests. Nat Commun 2022;13. [DOI: 10.1038/s41467-022-32663-9] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
9 Wang X, Wang S, Wang J, Rong L. A Multiscale Model of COVID-19 Dynamics. Bull Math Biol 2022;84:99. [PMID: 35943625 DOI: 10.1007/s11538-022-01058-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 García-crespo C, Vázquez-sirvent L, Somovilla P, Soria ME, Gallego I, de Ávila AI, Martínez-gonzález B, Durán-pastor A, Domingo E, Perales C. Efficacy decrease of antiviral agents when administered to ongoing hepatitis C virus infections in cell culture. Front Microbiol 2022;13:960676. [DOI: 10.3389/fmicb.2022.960676] [Reference Citation Analysis]
11 Rahmah L, Abarikwu SO, Arero AG, Jibril AT, Fal A, Flisiak R, Makuku R, Marquez L, Mohamed K, Ndow L, Zarębska-michaluk D, Rezaei N, Rzymski P. Oral antiviral treatments for COVID-19: opportunities and challenges. Pharmacol Rep. [DOI: 10.1007/s43440-022-00388-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Guérin PJ, Mclean ARD, Rashan S, Lawal A, Watson JA, Strub-wourgaft N, White NJ. Definitions matter: Heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis. PLOS Glob Public Health 2022;2:e0000561. [DOI: 10.1371/journal.pgph.0000561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Korosec CS, Betti MI, Dick DW, Ooi HK, Moyles IR, Wahl LM, Heffernan JM. Multiple cohort study of hospitalized SARS-CoV-2 in-host infection dynamics: parameter estimates, sensitivity and the eclipse phase profile.. [DOI: 10.1101/2022.06.20.22276662] [Reference Citation Analysis]
14 Darquenne C, Borojeni AA, Colebank MJ, Forest MG, Madas BG, Tawhai M, Jiang Y. Aerosol Transport Modeling: The Key Link Between Lung Infections of Individuals and Populations. Front Physiol 2022;13:923945. [DOI: 10.3389/fphys.2022.923945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bai Y, Shen M, Zhang L. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment. Viruses 2022;14:763. [DOI: 10.3390/v14040763] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
16 Fain BG, Dobrovolny HM. GPU acceleration and data fitting: Agent-based models of viral infections can now be parameterized in hours. Journal of Computational Science 2022. [DOI: 10.1016/j.jocs.2022.101662] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Ader F, Bouscambert-duchamp M, Hites M, Peiffer-smadja N, Poissy J, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Fougerou C, Lê M, Peytavin G, Mercier N, Velou P, Tubiana S, Lescure X, Faure E, Nseir S, Richard J, Wallet F, Goehringer F, Lefèvre B, Kimmoun A, Raffi F, Gaborit B, Reignier J, Lanoix J, Andrejak C, Zerbib Y, Bani-sadr F, Mourvilliers B, Danion F, Ruch Y, Clere-jehl R, Le Moing V, Klouche K, Lacombe K, Martin-blondel G, Vardon-bounes F, Cabié A, Turmel J, Piroth L, Blot M, Botelho-nevers É, Gagneux-brunon A, Thiery G, Bénézit F, Gaci R, Mootien J, Gallien S, Garot D, Bouiller K, Epelboin L, Jauréguiberry S, Gaymard A, Verschelden G, Braz S, Ferreira Ribeiro JM, Joannidis M, Staub T, Altdorfer A, Greil R, Egle A, Guedj J, Noret M, Roncon-albuquerque R, Paiva J, Lina B, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F. Remdesivir for the treatment of hospitalised patients with COVID-19: final results from the DisCoVeRy randomised, controlled, open-label trial.. [DOI: 10.1101/2022.03.30.22273206] [Reference Citation Analysis]
18 Li H, Kuga K, Ito K. SARS-CoV-2 Dynamics in the Mucus Layer of the Human Upper Respiratory Tract Based on Host–Cell Dynamics. Sustainability 2022;14:3896. [DOI: 10.3390/su14073896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Schöning V, Kern C, Chaccour C, Hammann F. Effectiveness of Antiviral Therapy in Highly-Transmissible Variants of SARS-CoV-2: A Modeling and Simulation Study. Front Pharmacol 2022;13:816429. [PMID: 35222030 DOI: 10.3389/fphar.2022.816429] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 González-paz L, Alvarado MJ, Hurtado-león ML, Lossada C, Vera-villalobos J, Loroño M, Paz J, Jeffreys LN, Torres FJ, Alvarado YJ. Comparative study of SARS-CoV-2 infection in different cell types: Biophysical-computational approach to the role of potential receptors. Computers in Biology and Medicine 2022;142:105245. [DOI: 10.1016/j.compbiomed.2022.105245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Alexander P, Dobrovolny HM. Treatment of Respiratory Viral Coinfections. Epidemiologia 2022;3:81-96. [DOI: 10.3390/epidemiologia3010008] [Reference Citation Analysis]
22 Lowe DM, Brown LK, Chowdhury K, Davey S, Yee P, Ikeji F, Ndoutoumou A, Shah D, Lennon A, Rai A, Agyeman AA, Checkley A, Longley N, Dehbi H, Freemantle N, Breuer J, Standing JF, FLARE Investigators. Favipiravir, lopinavir-ritonavir or combination therapy (FLARE): a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19.. [DOI: 10.1101/2022.02.11.22270775] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Padmanabhan P, Desikan R, Dixit NM. Modeling how antibody responses may determine the efficacy of COVID-19 vaccines. Nat Comput Sci 2022;2:123-31. [DOI: 10.1038/s43588-022-00198-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
24 Fatehi F, Bingham RJ, Stockley PG, Twarock R. An age-structured model of hepatitis B viral infection highlights the potential of different therapeutic strategies. Sci Rep 2022;12:1252. [PMID: 35075156 DOI: 10.1038/s41598-021-04022-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Bartoletti M. 'ESCMID COVID-19 living guidelines: drug treatment and clinical management'- Author's reply. Clin Microbiol Infect 2022:S1198-743X(21)00733-3. [PMID: 35026374 DOI: 10.1016/j.cmi.2021.12.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Kirkby C. A model of infection and immune response to low dose radiation. Int J Radiat Biol 2022;:1-14. [PMID: 34995150 DOI: 10.1080/09553002.2022.2020361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Farhang-sardroodi S, Ghaemi MS, Craig M, Ooi HK, Heffernan JM. . MBE 2022;19:5813-31. [DOI: 10.3934/mbe.2022272] [Reference Citation Analysis]
28 Frank TD. Virus Dynamics in Humans: Unstable Directions and Order Parameters. Understanding Complex Systems 2022. [DOI: 10.1007/978-3-030-97178-6_10] [Reference Citation Analysis]
29 Frank TD. Models of Virus Dynamics. Understanding Complex Systems 2022. [DOI: 10.1007/978-3-030-97178-6_9] [Reference Citation Analysis]
30 Zhang L, Li R, Song G, Scholes GD, She ZS. Impairment of T cells' antiviral and anti-inflammation immunities may be critical to death from COVID-19. R Soc Open Sci 2021;8:211606. [PMID: 34950497 DOI: 10.1098/rsos.211606] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
31 Rao R, Musante CJ, Allen R. A Quantitative Systems Pharmacology Model of the Pathophysiology and Treatment of COVID-19 Predicts Optimal Timing of Pharmacological Interventions.. [DOI: 10.1101/2021.12.07.21267277] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. Proc Natl Acad Sci U S A 2021;118:e2111477118. [PMID: 34857628 DOI: 10.1073/pnas.2111477118] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 33.0] [Reference Citation Analysis]
33 Ishak A, AlRawashdeh MM, Esagian SM, Nikas IP. Diagnostic, Prognostic, and Therapeutic Value of Droplet Digital PCR (ddPCR) in COVID-19 Patients: A Systematic Review. J Clin Med 2021;10:5712. [PMID: 34884414 DOI: 10.3390/jcm10235712] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rodriguez T, Dobrovolny HM. Estimation of viral kinetics model parameters in young and aged SARS-CoV-2 infected macaques. R Soc Open Sci 2021;8:202345. [PMID: 34804559 DOI: 10.1098/rsos.202345] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
35 Salasc F, Lahlali T, Laurent E, Rosa-Calatrava M, Pizzorno A. Treatments for COVID-19: Lessons from 2020 and new therapeutic options. Curr Opin Pharmacol 2021;62:43-59. [PMID: 34915400 DOI: 10.1016/j.coph.2021.11.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
36 Alexandre M, Marlin R, Prague M, Coleon S, Kahlaoui N, Cardinaud S, Naninck T, Delache B, Surenaud M, Galhaut M, Dereuddre-bosquet N, Cavarelli M, Maisonnasse P, Centlivre M, Lacabaratz C, Wiedemann A, Zurawski S, Zurawski G, Schwartz O, Sanders RW, Le Grand R, Levy Y, Thiébaut R. SARS-CoV-2 mechanistic correlates of protection: insight from modelling response to vaccines.. [DOI: 10.1101/2021.10.29.466418] [Reference Citation Analysis]
37 Lingas G, Néant N, Gaymard A, Belhadi D, Peytavin G, Hites M, Staub T, Greil R, Paiva J, Poissy J, Peiffer-smadja N, Costagliola D, Yazdanpanah Y, Wallet F, Gagneux-brunon A, Mentré F, Ader F, Burdet C, Guedj J, Bouscambert-duchamp M, the DisCoVeRy study group. Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial.. [DOI: 10.1101/2021.10.19.21265209] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Jeong YD, Ejima K, Kim KS, Iwanami S, Iwami S, Aihara K. Safely return to schools and offices: early and frequent screening with high sensitivity antigen tests effectively identifies COVID-19 patients.. [DOI: 10.1101/2021.10.08.21264782] [Reference Citation Analysis]
39 Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-Monné M, Marks M, Guedj J. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness. Elife 2021;10:e69302. [PMID: 34569939 DOI: 10.7554/eLife.69302] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 37.0] [Reference Citation Analysis]
40 Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis 2021:S1473-3099(21)00485-0. [PMID: 34534511 DOI: 10.1016/S1473-3099(21)00485-0] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 76.0] [Reference Citation Analysis]
41 Fatehi F, Bingham RJ, Dykeman EC, Stockley PG, Twarock R. Comparing antiviral strategies against COVID-19 via multiscale within-host modelling. R Soc Open Sci 2021;8:210082. [PMID: 34430042 DOI: 10.1098/rsos.210082] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
42 Tomasa-Irriguible TM, Bielsa-Berrocal L, Bordejé-Laguna L, Tural-Llàcher C, Barallat J, Manresa-Domínguez JM, Torán-Monserrat P. Low Levels of Few Micronutrients May Impact COVID-19 Disease Progression: An Observational Study on the First Wave. Metabolites 2021;11:565. [PMID: 34564381 DOI: 10.3390/metabo11090565] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
43 Boshier FAT, Pang J, Penner J, Parker M, Alders N, Bamford A, Grandjean L, Grunewald S, Hatcher J, Best T, Dalton C, Bynoe PD, Frauenfelder C, Köeglmeier J, Myerson P, Roy S, Williams R, de Silva TI, Goldstein RA, Breuer J; COVID-19 Genomics UK (COG-UK) consortium. Evolution of viral variants in remdesivir-treated and untreated SARS-CoV-2-infected pediatrics patients. J Med Virol 2021. [PMID: 34415583 DOI: 10.1002/jmv.27285] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
44 Vaidya NK, Bloomquist A, Perelson AS. Modeling Within-Host Dynamics of SARS-CoV-2 Infection: A Case Study in Ferrets. Viruses 2021;13:1635. [PMID: 34452499 DOI: 10.3390/v13081635] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
45 Kim KS, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T, Ejima K, Iwami S. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Sci Alliance 2021;4:e202101049. [PMID: 34344719 DOI: 10.26508/lsa.202101049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
46 Jeong YD, Ejima K, Kim KS, Iwanami S, Bento AI, Fujita Y, Jung IH, Aihara K, Watashi K, Miyazaki T, Wakita T, Iwami S, Ajelli M. Revisiting the guidelines for ending isolation for COVID-19 patients. Elife 2021;10:e69340. [PMID: 34311842 DOI: 10.7554/eLife.69340] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
47 Altulea D, Maassen S, Baranov MV, van den Bogaart G. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology. J Mol Cell Biol 2021;13:175-84. [PMID: 33693723 DOI: 10.1093/jmcb/mjab016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
48 Iwanami S, Ejima K, Kim KS, Noshita K, Fujita Y, Miyazaki T, Kohno S, Miyazaki Y, Morimoto S, Nakaoka S, Koizumi Y, Asai Y, Aihara K, Watashi K, Thompson RN, Shibuya K, Fujiu K, Perelson AS, Iwami S, Wakita T. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med 2021;18:e1003660. [PMID: 34228712 DOI: 10.1371/journal.pmed.1003660] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
49 Reeves DB, Rolland M, Dearlove BL, Li Y, Robb ML, Schiffer JT, Gilbert P, Cardozo-Ojeda EF, Mayer BT. Timing HIV infection with a simple and accurate population viral dynamics model. J R Soc Interface 2021;18:20210314. [PMID: 34186015 DOI: 10.1098/rsif.2021.0314] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
50 Ke R, Zitzmann C, Ho DD, Ribeiro RM, Perelson AS. In vivo kinetics of SARS-CoV-2 infection and its relationship with a person's infectiousness. medRxiv 2021:2021. [PMID: 34230935 DOI: 10.1101/2021.06.26.21259581] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
51 Fang FC, Benson CA, Del Rio C, Edwards KM, Fowler VG, Fredricks DN, Limaye AP, Murray BE, Naggie S, Pappas PG, Patel R, Paterson DL, Pegues DA, Petri WA, Schooley RT. COVID-19-Lessons Learned and Questions Remaining. Clin Infect Dis 2021;72:2225-40. [PMID: 33104186 DOI: 10.1093/cid/ciaa1654] [Cited by in Crossref: 29] [Cited by in F6Publishing: 36] [Article Influence: 29.0] [Reference Citation Analysis]
52 Chatterjee B, Sandhu HS, Dixit NM. The relative strength and timing of innate immune and CD8 T-cell responses underlie the heterogeneous outcomes of SARS-CoV-2 infection.. [DOI: 10.1101/2021.06.15.21258935] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
53 Cao Y, Gao W, Caro L, Stone JA. Immune-viral dynamics modeling for SARS-CoV-2 drug development. Clin Transl Sci 2021. [PMID: 34121337 DOI: 10.1111/cts.13099] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
54 Sender R, Bar-On YM, Gleizer S, Bernshtein B, Flamholz A, Phillips R, Milo R. The total number and mass of SARS-CoV-2 virions. Proc Natl Acad Sci U S A 2021;118:e2024815118. [PMID: 34083352 DOI: 10.1073/pnas.2024815118] [Cited by in Crossref: 79] [Cited by in F6Publishing: 95] [Article Influence: 79.0] [Reference Citation Analysis]
55 Seddighi Chaharborj S, Seddighi Chaharborj S, Hassanzadeh Asl J, Phang PS. Controlling of pandemic COVID-19 using optimal control theory. Results Phys 2021;26:104311. [PMID: 34094820 DOI: 10.1016/j.rinp.2021.104311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Guérin PJ, Mclean AR, Rashan S, Lawal A, Watson JA, Strub-wourgaft N, White NJ. Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis.. [DOI: 10.1101/2021.06.04.21257852] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
57 Abuin P, Anderson A, Ferramosca A, Hernandez-Vargas EA, Gonzalez AH. Dynamical characterization of antiviral effects in COVID-19. Annu Rev Control 2021. [PMID: 34093069 DOI: 10.1016/j.arcontrol.2021.05.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Chatterjee AN, Basir FA, Almuqrin MA, Mondal J, Khan I. SARS-CoV-2 infection with lytic and non-lytic immune responses: A fractional order optimal control theoretical study. Results Phys 2021;26:104260. [PMID: 34055582 DOI: 10.1016/j.rinp.2021.104260] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
59 Lim XY, Chan JSW, Tan TYC, Teh BP, Mohd Abd Razak MR, Mohamad S, Syed Mohamed AF. Andrographis paniculata (Burm. F.) Wall. Ex Nees, Andrographolide, and Andrographolide Analogues as SARS-CoV-2 Antivirals? A Rapid Review. Natural Product Communications 2021;16:1934578X2110166. [DOI: 10.1177/1934578x211016610] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
60 Marc A, Kerioui M, Blanquart F, Bertrand J, Mitjà O, Corbacho-monné M, Marks M, Guedj J. Quantifying the relationship between SARS-CoV-2 viral load and infectiousness.. [DOI: 10.1101/2021.05.07.21256341] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
61 Gallo JM. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2. Clin Transl Sci 2021;14:1082-91. [PMID: 33404204 DOI: 10.1111/cts.12975] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
62 Gastine S, Pang J, Boshier FAT, Carter SJ, Lonsdale DO, Cortina-Borja M, Hung IFN, Breuer J, Kloprogge F, Standing JF. Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies. Clin Pharmacol Ther 2021;110:321-33. [PMID: 33641159 DOI: 10.1002/cpt.2223] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
63 Zhang L, Li R, Song G, Scholes GD, She Z. Impairment of T cells’ antiviral and anti-inflammation immunities dominates death from COVID-19.. [DOI: 10.1101/2021.04.26.21256093] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Ejima K, Kim KS, Iwanami S, Fujita Y, Li M, Zoh RS, Aihara K, Miyazaki T, Wakita T, Iwami S. Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. J R Soc Interface 2021;18:20200947. [PMID: 33878277 DOI: 10.1098/rsif.2020.0947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
65 Sender R, Bar-On YM, Gleizer S, Bernsthein B, Flamholz A, Phillips R, Milo R. The total number and mass of SARS-CoV-2 virions. medRxiv 2021:2020. [PMID: 33236021 DOI: 10.1101/2020.11.16.20232009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
66 Hache G, Rolain JM, Gautret P, Deharo JC, Brouqui P, Raoult D, Honoré S. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity. Microb Drug Resist 2021;27:281-90. [PMID: 33729874 DOI: 10.1089/mdr.2020.0232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
67 Ceccarelli G, Alessandri F, Oliva A, Borrazzo C, Dell'Isola S, Ialungo AM, Rastrelli E, Pelli M, Raponi G, Turriziani O, Ruberto F, Rocco M, Pugliese F, Russo A, d'Ettorre G, Venditti M. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). J Med Virol 2021;93:4319-25. [PMID: 33675235 DOI: 10.1002/jmv.26925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
68 Lim XY, Teh BP, Tan TYC. Medicinal Plants in COVID-19: Potential and Limitations. Front Pharmacol 2021;12:611408. [PMID: 33841143 DOI: 10.3389/fphar.2021.611408] [Cited by in Crossref: 18] [Cited by in F6Publishing: 22] [Article Influence: 18.0] [Reference Citation Analysis]
69 Kim KS, Ejima K, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Asai Y, Nakaoka S, Watashi K, Aihara K, Thompson RN, Ke R, Perelson AS, Iwami S. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol 2021;19:e3001128. [PMID: 33750978 DOI: 10.1371/journal.pbio.3001128] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 53.0] [Reference Citation Analysis]
70 Ejima K, Kim KS, Ludema C, Bento AI, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Watashi K, Aihara K, Nishiura H, Iwami S. Estimation of the incubation period of COVID-19 using viral load data. Epidemics 2021;35:100454. [PMID: 33773195 DOI: 10.1016/j.epidem.2021.100454] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
71 Kern C, Schöning V, Chaccour C, Hammann F. Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. Front Pharmacol 2021;12:625678. [PMID: 33776767 DOI: 10.3389/fphar.2021.625678] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
72 Friberg LE. Pivotal Role of Translation in Anti‐Infective Development. Clin Pharmacol Ther 2021;109:856-66. [DOI: 10.1002/cpt.2182] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
73 Perelson AS, Ke R. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics. Clin Pharmacol Ther 2021;109:829-40. [PMID: 33410134 DOI: 10.1002/cpt.2160] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 30.0] [Reference Citation Analysis]
74 Czuppon P, Débarre F, Gonçalves A, Tenaillon O, Perelson AS, Guedj J, Blanquart F. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action. PLoS Comput Biol 2021;17:e1008752. [PMID: 33647008 DOI: 10.1371/journal.pcbi.1008752] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 22.0] [Reference Citation Analysis]
75 Dodds M, Xiong Y, Mouksassi S, Kirkpatrick CM, Hui K, Doyle E, Patel K, Cox E, Wesche D, Brown F, Rayner CR. Model-informed drug repurposing: A pharmacometric approach to novel pathogen preparedness, response and retrospection. Br J Clin Pharmacol 2021;87:3388-97. [PMID: 33534138 DOI: 10.1111/bcp.14760] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
76 Néant N, Lingas G, Le Hingrat Q, Ghosn J, Engelmann I, Lepiller Q, Gaymard A, Ferré V, Hartard C, Plantier JC, Thibault V, Marlet J, Montes B, Bouiller K, Lescure FX, Timsit JF, Faure E, Poissy J, Chidiac C, Raffi F, Kimmoun A, Etienne M, Richard JC, Tattevin P, Garot D, Le Moing V, Bachelet D, Tardivon C, Duval X, Yazdanpanah Y, Mentré F, Laouénan C, Visseaux B, Guedj J; French COVID Cohort Investigators and French Cohort Study groups. Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort. Proc Natl Acad Sci U S A 2021;118:e2017962118. [PMID: 33536313 DOI: 10.1073/pnas.2017962118] [Cited by in Crossref: 109] [Cited by in F6Publishing: 113] [Article Influence: 109.0] [Reference Citation Analysis]
77 Kuroda K, Li C, Dhangar K, Kumar M. Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters. Sci Total Environ 2021;776:145740. [PMID: 33647647 DOI: 10.1016/j.scitotenv.2021.145740] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 38.0] [Reference Citation Analysis]
78 Patel K, Dodds M, Gonçalves A, Kamal MA, Rayner CR, Kirkpatrick CM, Smith PF. Using in silico viral kinetic models to guide therapeutic strategies during a pandemic: An example in SARS-CoV-2. Br J Clin Pharmacol 2021;87:3425-38. [PMID: 33373059 DOI: 10.1111/bcp.14718] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
79 Voutouri C, Nikmaneshi MR, Hardin CC, Patel AB, Verma A, Khandekar MJ, Dutta S, Stylianopoulos T, Munn LL, Jain RK. In silico dynamics of COVID-19 phenotypes for optimizing clinical management. Proc Natl Acad Sci U S A 2021;118:e2021642118. [PMID: 33402434 DOI: 10.1073/pnas.2021642118] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 20.0] [Reference Citation Analysis]
80 Xia H, Shi PY. Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2. J Interferon Cytokine Res 2020;40:543-8. [PMID: 33337934 DOI: 10.1089/jir.2020.0214] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 19.0] [Reference Citation Analysis]
81 Bose D, Gogtay NJ, Rajan SK. Placing the results of the SOLIDARITY trial with regards to remdesivir in perspective. Lung India 2021;38:382-6. [PMID: 34259182 DOI: 10.4103/lungindia.lungindia_883_20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
82 Sego TJ, Aponte-Serrano JO, Ferrari Gianlupi J, Heaps SR, Breithaupt K, Brusch L, Crawshaw J, Osborne JM, Quardokus EM, Plemper RK, Glazier JA. A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness. PLoS Comput Biol 2020;16:e1008451. [PMID: 33347439 DOI: 10.1371/journal.pcbi.1008451] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
83 Metcalf CJE, Grenfell BT, Graham AL. Disentangling the dynamical underpinnings of differences in SARS-CoV-2 pathology using within-host ecological models. PLoS Pathog 2020;16:e1009105. [PMID: 33306746 DOI: 10.1371/journal.ppat.1009105] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
84 Padmanabhan P, Desikan R, Dixit NM. Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput Biol 2020;16:e1008461. [PMID: 33290397 DOI: 10.1371/journal.pcbi.1008461] [Cited by in Crossref: 52] [Cited by in F6Publishing: 60] [Article Influence: 26.0] [Reference Citation Analysis]
85 Tarek M, Savarino A. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention. Eur J Drug Metab Pharmacokinet 2020;45:715-23. [PMID: 32780273 DOI: 10.1007/s13318-020-00640-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
86 Goyal A, Cardozo-Ojeda EF, Schiffer JT. Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Sci Adv 2020;6:eabc7112. [PMID: 33097472 DOI: 10.1126/sciadv.abc7112] [Cited by in Crossref: 78] [Cited by in F6Publishing: 86] [Article Influence: 39.0] [Reference Citation Analysis]
87 Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, Pandak N, Al Balushi Z, Al Bahrani M, Al Salmi I, Al-Zakwani I. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis 2021;102:538-43. [PMID: 33181328 DOI: 10.1016/j.ijid.2020.11.008] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 24.5] [Reference Citation Analysis]
88 Fain B, Dobrovolny HM. Initial Inoculum and the Severity of COVID-19: A Mathematical Modeling Study of the Dose-Response of SARS-CoV-2 Infections. Epidemiologia 2020;1:5-15. [DOI: 10.3390/epidemiologia1010003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
89 Hernandez-Vargas EA, Velasco-Hernandez JX. In-host Mathematical Modelling of COVID-19 in Humans. Annu Rev Control 2020;50:448-56. [PMID: 33020692 DOI: 10.1016/j.arcontrol.2020.09.006] [Cited by in Crossref: 82] [Cited by in F6Publishing: 92] [Article Influence: 41.0] [Reference Citation Analysis]
90 Sego TJ, Aponte-Serrano JO, Gianlupi JF, Heaps SR, Breithaupt K, Brusch L, Crawshaw J, Osborne JM, Quardokus EM, Plemper RK, Glazier JA. A modular framework for multiscale, multicellular, spatiotemporal modeling of acute primary viral infection and immune response in epithelial tissues and its application to drug therapy timing and effectiveness: A multiscale model of viral infection in epithelial tissues. bioRxiv 2020:2020. [PMID: 32511367 DOI: 10.1101/2020.04.27.064139] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
91 Heimfarth L, Serafini MR, Martins-Filho PR, Quintans JSS, Quintans-Júnior LJ. Drug repurposing and cytokine management in response to COVID-19: A review. Int Immunopharmacol 2020;88:106947. [PMID: 32919216 DOI: 10.1016/j.intimp.2020.106947] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
92 Gastine S, Pang J, Boshier FA, Carter SJ, Lonsdale DO, Cortina-borja M, Hung IF, Breuer J, Kloprogge F, Standing JF. Systematic review and patient-level meta-analysis of SARS-CoV-2 viral dynamics to model response to antiviral therapies.. [DOI: 10.1101/2020.08.20.20178699] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Dobrovolny HM. Quantifying the effect of remdesivir in rhesus macaques infected with SARS-CoV-2. Virology 2020;550:61-9. [PMID: 32882638 DOI: 10.1016/j.virol.2020.07.015] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]
94 Dodds MG, Krishna R, Goncalves A, Rayner CR. Model-informed drug repurposing: Viral kinetic modelling to prioritize rational drug combinations for COVID-19. Br J Clin Pharmacol 2021;87:3439-50. [PMID: 32693436 DOI: 10.1111/bcp.14486] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
95 Rosenbloom DS, Zhao P, Sinha V. Initiation of Antiviral Treatment in SARS-CoV2: Modeling Viral Dynamics and Drug Properties. CPT Pharmacometrics Syst Pharmacol 2020;9:481-3. [PMID: 32700405 DOI: 10.1002/psp4.12550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Fang FC, Schooley RT. Treatment of COVID-19 - Evidence-Based or Personalized Medicine? Clin Infect Dis 2020:ciaa996. [PMID: 32667978 DOI: 10.1093/cid/ciaa996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
97 Hughes JH, Sweeney K, Ahadieh S, Ouellet D. Predictions of Systemic, Intracellular, and Lung Concentrations of Azithromycin With Different Dosing Regimens Used in COVID-19 Clinical Trials. CPT Pharmacometrics Syst Pharmacol 2020;9:435-43. [PMID: 32511867 DOI: 10.1002/psp4.12537] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
98 Oscanoa TJ, Romero-Ortuno R, Carvajal A, Savarino A. A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus? Int J Antimicrob Agents 2020;56:106078. [PMID: 32629115 DOI: 10.1016/j.ijantimicag.2020.106078] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 13.5] [Reference Citation Analysis]
99 Hartman D, Kern S, Brown F, Minton SK, Rayner CR. Time to Step Up: A Call to Action For the Clinical and Quantitative Pharmacology Community to Accelerate Therapeutics for COVID-19. Clin Transl Sci 2020;13:646-8. [PMID: 32441462 DOI: 10.1111/cts.12824] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
100 Czuppon P, Débarre F, Gonçalves A, Tenaillon O, Perelson AS, Guedj J, Blanquart F. Predicted success of prophylactic antiviral therapy to block or delay SARS-CoV-2 infection depends on the drug’s mechanism of action.. [DOI: 10.1101/2020.05.07.20092965] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]